Company intelligence / Profile preview

Shanghai Medicilon

Shanghai, Shanghai, Chinamedicilon.com ↗

Ownership: Private
Employees: ~2400
Development stage: Commercial

Overview

Shanghai Medicilon provides comprehensive preclinical contract research services covering drug discovery through IND-enabling studies. The company supports global pharmaceutical and biotech clients with integrated solutions including chemical synthesis, compound screening/optimization, structural biology research, CMC development and GMP-compliant API manufacturing. Their facilities are GLP-certified by both Chinese NMPA and US FDA. They do not develop their own drugs but enable client pipelines from early discovery to IND submission.

Modalities: Small moleculeBiologicAntibody-drug conjugatePROTAC technology (Proteolysis-targeting chimera therapy)DNA-encoded library screening compounds
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Shanghai Medicilon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Medicilon.

Explore the full profile